Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects

Drug Delivery

Volumn 20, Issue 5, 2013, Pages 216-223

  Nave, Ruediger ^a   Schmitt, Holger ^a   Popper, Lars ^b  

^a Nycomed: A Takeda Company   (Germany)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Breakthrough cancer pain; Drug delivery system; Incomplete consumption of oral transmucosal fentanyl citrate; Pharmacokinetics; Single dose delivery system

Indexed keywords

FENTANYL; FENTANYL CITRATE; NALTREXONE;

ABSENCE OF SIDE EFFECTS; ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LOZENGE; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ABSORPTION; ADMINISTRATION, BUCCAL; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANALGESICS, OPIOID; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FENTANYL; HUMANS; MALE;

EID: 84879587545     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.762435     Document Type: Article

References (35)

1. Agu R.U. Ugwolke M.I. 2008 In situ and ex-vivo nasal models for preclinical drug development studies Ehrhardt C, Kim KJ Drug Absorption Studies: In Situ, in Vitro and in Silico Models New York: Springer 216-234
2. Agu RU, Ugwolke MI. (2008). In situ and ex-vivo nasal models for preclinical drug development studies. In: Ehrhardt C, Kim KJ, eds. Drug absorption studies: in situ, in vitro and in silico models. New York: Springer, 216-34. Bennett D, Burton AW, Fishman S, et al. (2005). Consensus panel recommendation for the assessment and management of breakthrough pain. Part 2: management. Pharm Ther 30:354-61. (Pubitemid 40885216)
3. Chaushu G, Bercovici M, Dori S, et al. (2000). Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer 88:984-7. (Pubitemid 30127656)
4. Christrup LL, Foster D, Popper LD, et al. (2008). Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin Ther 30:469-81. (Pubitemid 351483922)
5. Coluzzi PH, Schwartzberg L, Conroy JD, et al. (2001). Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91:123-30. (Pubitemid 32274181)
6. Dale O, Hjortkjær R, Kharasch ED. (2002). Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46:759-70. (Pubitemid 34803193)
7. Darwish M, Kirby M, Robertson P, et al. (2007). Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 47:343-50. (Pubitemid 46294716)
8. Davies A, Dickman A, Reid C, et al. (2009). The management of cancerrelated breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331-8.
9. Davies AN, Vriens J. (2005). Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage 30:496-7. (Pubitemid 41821200)
10. European Medical Agency. (2011). Instanyl-(intranasal fentanyl spray): summary of product characteristics. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000959/ WC500033141.pdf [last accessed July 2011].
11. Fisher A, Watling M, Smith A, Knight A. (2010). Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100-800 mg in healthy volunteers. Int J Clin Pharmacol Ther 48:860-7.
12. FDA. (2011). Actiq-approved US prescribing information. Available from: http://www.actiq.com/pdf/actiq-package-insert-4-5-07.pdf [last accessed Dec 2011].
13. Foster D, Upton R, Christrup L, Popper L. (2008). Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 42:1380-7.
14. Gomez-Batiste X, Madrid F, Moreno F, et al. (2002). Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 24:45-52.
15. Hanks G. (2001). Oral transmucosal fentanyl citrate for the management of breakthrough pain. Eur J Palliat Care 8:6-9.
16. Kaasa S, Moksnes K, Nolte T, et al. (2010). Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 6:17-26.
17. Kaessner N, Nave R, Roepcke S, et al. (2012). Population pharmacokinetic meta-analysis of intranasal fentanyl spray as means to enrich pharmacokinetic information for patients with cancer breakthrough pain. Int J Clin Pharmacol Ther 50:665-77.
18. Kress HG, Oronska A, Kaczmarek Z, et al. (2009). Efficacy and tolerability of intranasal fentanyl spray 50 to 200 mg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 31:1177-91.
19. Mather LE. (1983). Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmcokinet 8:422-46. (Pubitemid 13009122)
20. Mercadante S, Radbruch L, Caraceni A, et al. (2002). Episodic (breakthrough pain): consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832-9. (Pubitemid 34132314)
21. Mercadante S, Radbruch L, Davies A, et al. (2009). A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 25:2805-15.
22. Moksnes K, Fredheim OM, Klepstad P, et al. (2008). Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol 64:497-502.
23. Nave R, Connolly SM, Popper L, et al. (2012). Single-dose and multidose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study. Int J Clin Pharmacol Ther 50:751-9.
24. Nave R, Popper L, Lahu G, Schmitt H. (2011). No apparent differences in pharmacokinetics of intranasal fentanyl spray investigating nasaldripping after administrating up to 400 mL per nostril. Eur J Pain 5:S611.
25. Nave R, Sides EH, Colberg T, et al. (2009a). Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Eur J Pain 13:S207.
26. Nave R, Sides EH, Colberg T, et al. (2009b). Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Eur J Pain 13:S207.
27. Patt RB, Ellison NM. (1998). Breakthrough pain in cancer patients: characteristics, prevalence, and treatment. Oncology 12:1035-46. (Pubitemid 128617904)
28. Portenoy RK, Hagen NA. (1990). Breakthrough pain: definition, prevalence and characteristics. Pain 41:273-81. (Pubitemid 20187930)
29. Simmonds MA. (1999). Management of breakthrough pain due to cancer. Oncology 13:1103-8.
30. Streisand JB, Busch M, Egan TD, et al. (1998). Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88:305-9. (Pubitemid 28081188)
31. Sweeney MP, Bagg J, Baxter WP, Aitchison TC. (1998). Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 34:123-6. (Pubitemid 28207012)
32. Walker G, Wilcock A, Manderson C, et al. (2003). The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 17:219-21. (Pubitemid 36432601)
33. World Medical Association Declaration of Helsinki. (1964). Ethical principles for medical research involving human subjects. Helsinki 1964, amended in Tokyo 1975, Venice 1983, Hong Kong 1989, South Africa 1996, Edinburgh 2000, Washington 2002, Tokyo 2004.
34. Zeppetella G, O'Doherty CA, Collins S. (2000). Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20:87-92.
35. Zeppetella G, Ribeiro MD. (2003). Pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother 4:493-502. (Pubitemid 36511979)